journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Clinical Oncology

journal
https://read.qxmd.com/read/30993483/cell-type-specific-sensitivity-of-bortezomib-in-the-methotrexate-resistant-primary-central-nervous-system-lymphoma-cells
#1
Azusa Hayano, Yasuo Takashima, Ryuya Yamanaka
BACKGROUND: Methotrexate (MTX) is used in first-line treatment of primary central nervous system lymphoma (PCNSL), but most cases result in relapse-acquired resistance to MTX. However, only few studies have reported on internal changes and chemotherapies in PCNSL. METHODS: In this study, we generated two MTX-resistant PCNSL cell lines, designated MTX-HKBML and MTX-TK, in addition to a MTX-resistant Burkitt lymphoma cell line, designated MTX-RAJI. We examined gene expression changes and drug sensitivity to a proteasome inhibitor, bortezomib, in these cells...
April 16, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30993482/feasibility-of-initial-treatment-in-elderly-patients-with-ovarian-cancer-in-japan-a-retrospective-study
#2
Seiko Bun, Mayu Yunokawa, Takahiro Ebata, Mayumi Kobayashi Kato, Tatsunori Shimoi, Tomoyasu Kato, Kenji Tamura
PURPOSE: The purpose of this study was to evaluate the real world situation and clarify the problem in initial treatment for elderly patients with ovarian cancer in Japan. METHODS: We used the ovarian cancer database, containing all patients diagnosed and treated with International Federation of Gynecology and Obstetrics Stage I-IV ovarian cancer at the National Cancer Center Hospital in Japan from June 2008 to April 2013. Patients were stratified into two groups based on age: an elderly group, aged 70 years or older, and a younger group, aged below 70 years...
April 15, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30982153/cryosurgery-for-primary-breast-cancers-its-biological-impact-and-clinical-outcomes
#3
REVIEW
Masahiro Takada, Masakazu Toi
Recently, a number of new minimally invasive image-guided percutaneous ablation treatments, including cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, laser ablation, and irreversible electroporation have been developed. Several studies have shown the feasibility and safety of these cryoablation therapies for the treatment of benign breast tumors and small invasive breast cancer. Although the complete response rate of cryoablation for breast cancer is reported to be relatively good, most studies enrolled a small number of patients, and so reliable conclusions could not be drawn...
April 13, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30980196/molecular-carcinogenesis-of-gastric-cancer-lauren-classification-mucin-phenotype-expression-and-cancer-stem-cells
#4
REVIEW
Naohide Oue, Kazuhiro Sentani, Naoya Sakamoto, Naohiro Uraoka, Wataru Yasui
Gastric cancer (GC), one of the most common human cancers, is a heterogeneous disease with different phenotypes, prognoses, and responses to treatment. Understanding the pathogenesis of GC at the molecular level is important for prognosis prediction and determining treatments. Microsatellite instability (MSI), silencing of MLH1, MGMT, and CDKN2A genes by DNA hypermethylation, KRAS mutation, APC mutation, and ERBB2 amplification are frequently found in intestinal type GC. Inactivation of CDH1 and RARB by DNA hypermethylation, and amplification of FGFR and MET, are frequently detected in diffuse type GC...
April 12, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30976939/dawn-of-precision-medicine-on-gastric-cancer
#5
REVIEW
Takahiro Ishii, Akihito Kawazoe, Kohei Shitara
BACKGROUND: In recent years, a better understanding of tumor biology and molecular features of gastric cancer has been reached. It may serve as a roadmap for patient stratification and trials of targeted therapies. The apparent efficacy of PD-1 blockade might be limited to a relatively small subset of advanced gastric cancer patients. MATERIALS AND METHODS: In this study, preclinical and clinical studies, which investigated molecular features, promising treatment targets, and immune checkpoint inhibitor in gastric cancer, were reviewed via PubMed and the congress webpages of the American Society of Clinical Oncology and European Society of Medical Oncology...
April 11, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30976938/high-diagnostic-efficacy-of-5-aminolevulinic-acid-induced-fluorescent-urine-cytology-for-urothelial-carcinoma
#6
Gaku Yamamichi, Wataru Nakata, Masaru Tani, Go Tsujimura, Yuichi Tsujimoto, Mikio Nin, Akihiro Mimura, Hideaki Miwa, Masao Tsujihata
BACKGROUND: In general, urine cytology is often problematic because of its low sensitivity, especially for low-grade urothelial carcinoma (UC) in clinical practice. To improve the sensitivity, we focused on 5-aminolevulinic acid (5-ALA), because recent studies suggested that 5-ALA-induced urine cytology can be used for photodynamic diagnosis. In this study, we evaluated the diagnostic efficacy of 5-ALA-induced fluorescent urine cytology for UC. METHODS: We included in this study 318 patients comprising 158 non-cancer patients, 84 bladder tumor patients, and 76 upper urinary tract urothelial carcinoma (UUT-UC) patients treated in our institution from March 2013 to September 2018...
April 11, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30972506/predictive-factors-for-short-term-biochemical-recurrence-free-survival-after-robot-assisted-laparoscopic-radical-prostatectomy-in-high-risk-prostate-cancer-patients
#7
Mitsugu Kanehira, Ryo Takata, Shuhei Ishii, Akito Ito, Daiki Ikarashi, Tomohiko Matsuura, Yoichiro Kato, Wataru Obara
BACKGROUND: We aimed to assess the short-term oncological outcomes of robot-assisted laparoscopic radical prostatectomy to determine the predictive factors associated with biochemical recurrence in high-risk prostate cancer patients. METHODS: A total of 331 patients with localized prostate cancer underwent robot-assisted laparoscopic radical prostatectomy. Of them, 113 patients were diagnosed with high-risk prostate cancer according to the D'Amico risk group classification...
April 10, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30972505/laparoscopic-radical-cystectomy-in-octogenarians-analysis-of-a-japanese-multicenter-cohort
#8
Katsuhiro Ito, Toru Kanno, Atsuro Sawada, Ryoichi Saito, Takashi Kobayashi, Hitoshi Yamada, Takahiro Inoue, Osamu Ogawa
BACKGROUNDS: This study aimed to describe the morbidity and mortality in older patients undergoing laparoscopic radical cystectomy (LRC) and compare the outcomes of LRC between octogenarians and younger patients (< 80 years) in a Japanese multicenter cohort. METHODS: We identified 433 patients (80 octogenarians) who underwent LRC in a retrospective multicenter database from 10 institutions. The perioperative outcomes and the 90-day and late (> 90-day) complications according to the Clavien-Dindo classification were compared between the octogenarians and younger patients...
April 10, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30968270/carbon-ion-radiotherapy-for-lymph-node-oligo-recurrence-a-multi-institutional-study-by-the-japan-carbon-ion-radiation-oncology-study-group-j-cros
#9
Noriyuki Okonogi, Takuya Kaminuma, Tomoaki Okimoto, Makoto Shinoto, Naoyoshi Yamamoto, Shigeru Yamada, Kazutoshi Murata, Tatsuya Ohno, Yoshiyuki Shioyama, Hiroshi Tsuji, Takashi Nakano, Tadashi Kamada
BACKGROUND: The efficacy of carbon-ion radiotherapy (C-ion RT) for lymph node (LN) oligo-recurrence has only been evaluated in limited single-center studies. We aimed to investigate the benefit of C-ion RT for LN oligo-recurrence in a large multi-center study. METHODS: Patients who received C-ion RT between December 1996 and December 2015 at 4 participating facilities and who met the following eligibility criteria were included: (i) histological or clinical diagnosis of LN recurrence; (ii) controlled primary lesion; (iii) no recurrence other than LN; (iv) LN recurrence involved in a single lymphatic site; and (v) age ≥ 20 years...
April 9, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30953238/real-world-treatment-of-over-1600-japanese-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-with-daily-afatinib
#10
Kazuo Tamura, Toshihiro Nukiwa, Akihiko Gemma, Nobuyuki Yamamoto, Masaya Mizushima, Kaori Ochai, Rie Ikeda, Hisaya Azuma, Yoichi Nakanishi
BACKGROUND: This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice. METHODS: This non-interventional study (NCT02131259) enrolled treatment-naïve and pre-treated patients with inoperable/recurrent EGFR mutation-positive NSCLC, eligible for afatinib treatment as per the afatinib label in Japan. Patients received afatinib at the approved dose (20, 30, 40, or 50 mg/day; physician decision), and were observed following treatment initiation for 52 weeks or until premature discontinuation...
April 5, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30941534/comparison-of-long-term-oncologic-outcomes-between-metastatic-ovarian-carcinoma-originating-from-gastrointestinal-organs-and-advanced-mucinous-ovarian-carcinoma
#11
Hiroaki Kajiyama, Shiro Suzuki, Fumi Utsumi, Nobuhisa Yoshikawa, Kimihiro Nishino, Yoshiki Ikeda, Kaoru Niimi, Eiko Yamamoto, Michiyasu Kawai, Kiyosumi Shibata, Tetsuro Nagasaka, Fumitaka Kikkawa
BACKGROUND: Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage. MATERIALS AND METHODS: The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III-IV PmOC, were retrospectively analyzed...
April 2, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30937622/bortezomib-based-strategy-with-autologous-stem-cell-transplantation-for-newly-diagnosed-multiple-myeloma-a-phase-ii-study-by-the-japan-study-group-for-cell-therapy-and-transplantation-jsct-mm12
#12
Kazutaka Sunami, Morio Matsumoto, Shin-Ichi Fuchida, Eijiro Omoto, Hiroyuki Takamatsu, Yoko Adachi, Ilsong Choi, Naohito Fujishima, Toru Kiguchi, Toshihiro Miyamoto, Akio Maeda, Junji Suzumiya, Ryosuke Yamamura, Koji Nagafuji, Tomonori Nakazato, Yoshiaki Kuroda, Toshiaki Yujiri, Yasushi Takamatsu, Mine Harada, Koichi Akashi
BACKGROUND: The Japan Study Group for Cell Therapy and Transplantation (JSCT) organized a phase II study to evaluate the efficacy and safety of a treatment protocol (JSCT-MM12) for multiple myeloma (MM) patients who were previously untreated and transplantation-eligible. Since bortezomib-based therapy is known to be effective for MM, the protocol is intensified more than the previous protocol (JSCT-MM10) and comprised the subsequent treatments: bortezomib + cyclophosphamide + dexamethasone (VCD) induction; bortezomib + high-dose-melphalan (B-HDM) conditioning with autologous stem cell transplantation (ASCT); bortezomib + thalidomide + dexamethasone (VTD) consolidation; and lenalidomide (LEN) maintenance...
April 1, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30937621/identification-of-serpine1-plau-and-acta1-as-biomarkers-of-head-and-neck-squamous-cell-carcinoma-based-on-integrated-bioinformatics-analysis
#13
Ke Yang, Shizhou Zhang, Dongsheng Zhang, Qian Tao, Tianqi Zhang, Guijun Liu, Xingguang Liu, Tengda Zhao
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the six leading cancer by incidence worldwide. The 5-year survival rate of HNSCC patients remains less than 65% due to lack of symptoms in the early stage. Hence, biomarkers which can improve detection of HNSCC should improve clinical outcome. METHODS: Gene expression profiles (GSE6631, GSE58911) and the Cancer Genome Atlas (TCGA) HNSCC data were used for integrated bioinformatics analysis; the differentially expressed genes (DEGs) were then subjected to functional and pathway enrichment analysis, protein-protein interaction (PPI) network construction...
April 1, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30937620/stereotactic-body-radiotherapy-in-patients-with-chronic-obstructive-pulmonary-disease-and-interstitial-pneumonia-a-review
#14
REVIEW
Hiroshi Doi, Kiyoshi Nakamatsu, Yasumasa Nishimura
Stereotactic body radiation therapy (SBRT) can yield excellent local tumor control, as well as survival benefit comparable to that of surgery for early-stage lung cancer. However, in terms of toxicity, SBRT might lead to fatal radiation pneumonitis. Lung diseases, such as chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD), are major risk factors for lung cancer. However, these patients are typically not candidates for the gold-standard treatment option, lobectomy, because of the perioperative risks...
April 1, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30919257/efficacy-and-safety-of-oxaliplatin-based-regimen-versus-cisplatin-based-regimen-in-the-treatment-of-gastric-cancer-a-meta-analysis-of-randomized-controlled-trials
#15
REVIEW
Gongchen Wang, Binfeng Yang, Zhaoyuan Fu, Xin Wang, Zhiming Zhang
BACKGROUND: Cisplatin played an important role in the treatment of gastric cancer (GC). Oxaliplatin has been shown to be at least as effective as cisplatin for GC, with less toxicity and a better tolerability profile. We performed a meta-analysis to compare the efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of GC. METHODS: Databases of CNKI, CBM, VIP, Wanfang, PubMed, Embase, Cochrane Library were searched for eligible literatures from their establishments to November 2018...
March 27, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30903422/impact-of-prostate-cancer-radiotherapy-on-the-biological-behavior-and-specific-mortality-of-subsequent-bladder-cancer
#16
Xiaoxiao Guo, Min Liu, Huimin Hou, Shenjie Liu, Xianbo Zhang, Yaqun Zhang, Pengjie Wu, Cheng Pang, Jianye Wang
BACKGROUND: The impact of different radiotherapy modalities on the development and characteristics of second primary bladder cancers (BCa) and BCa-specific mortality (BCa-SM) remains unclear. Thus, we evaluated the incidence and biological behavior of subsequent BCa and related survival in patients who underwent radiation therapy for prostate cancer (PCa). METHODS: A total of 530,581 patients in the surveillance, epidemiology, and end results database with localized PCa between 1988 and 2013 were identified...
March 22, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30903421/future-projection-of-cancer-patients-with-cardiovascular-disease-in-japan-by-the-year-2039-a-pilot-study
#17
Yuji Okura, Tsugumi Takayama, Kazuyuki Ozaki, Hiroshi Tanaka, Akira Kikuchi, Toshihiro Saito, Toshiki Tanigawa, Yasumasa Takii, Hiroshi Seki, Tatsuya Takenouchi, Takaaki Chou, Nobuaki Sato, Naohito Tanabe, Tohru Minamino
BACKGROUND: The number of cancer patients in Japan is estimated to rise to 3.5 million by 2025. The disease burden may be further complicated by comorbidities caused by cardiovascular disease (CVD). Predicting the number of cancer patients with CVD can help anticipate future resource needs. METHODS: We used statistics derived from the Niigata Cancer Center CVD Study (2015) as well as population estimates from the National Cancer Center's Cancer Registry and Statistics survey of 2017 for convenience...
March 22, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30891652/removal-of-the-entire-internal-iliac-vessel-system-is-a-feasible-surgical-procedure-for-locally-advanced-ovarian-carcinoma-adhered-firmly-to-the-pelvic-sidewall
#18
Kyoko Nishikimi, Shinichi Tate, Ayumu Matsuoka, Makio Shozu
BACKGROUND: Ovarian carcinomas sometimes grow in the pelvic cavity, adhering firmly to the pelvic sidewall. These cases are often considered as inoperable or result in the incomplete resection because the tumors are not mobile. We performed en bloc resection of the tumors along with the entire internal iliac vessel system to achieve complete resection. METHODS: Twenty of 237 consecutive patients with FIGO stage II-IV ovarian, fallopian tubal, or primary peritoneal carcinoma who underwent cytoreductive surgery at Chiba University Hospital between January 2008 and December 2016 had locally advanced tumors adhered firmly to the pelvic sidewall...
March 20, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30888527/survival-and-chemotherapy-related-risk-of-second-primary-malignancy-in-breast-cancer-patients-a-seer-based-study
#19
Jin-Li Wei, Yi-Zhou Jiang, Zhi-Min Shao
BACKGROUND: With the improvement in the survival of breast cancer, developing second primary malignancy becomes a serious health issue. The aim of this study was to explore the survival of breast cancer patients with second primary malignancy, and to evaluate the impact of chemotherapy on the risk of different cancer sites. METHOD: Obtaining data from the Surveillance, Epidemiology, and End Results database, we calculated the standardized incidence ratio (SIR) for second primary malignancy in breast cancer survivors between 2000 and 2014...
March 19, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30875000/three-year-follow-up-of-a-phase-ii-study-of-radium-223-dichloride-in-japanese-patients-with-symptomatic-castration-resistant-prostate-cancer-and-bone-metastases
#20
Hirotsugu Uemura, Hiroji Uemura, Satsohi Nagamori, Yoshiaki Wakumoto, Go Kimura, Hiroaki Kikukawa, Akira Yokomizo, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Takashi Akagawa, Nobuaki Matsubara
BACKGROUND: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC. METHODS: Patients with symptomatic mCRPC, ≥ 2 bone metastases and no known visceral metastases received up to 6 injections of radium-223 (55 kBq/kg), one every 4 weeks. Adverse events (AEs) considered to be related to radium-223 were reported until 3 years after the first injection...
March 14, 2019: International Journal of Clinical Oncology
journal
journal
32641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"